Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.
Patients whose indolent lymphomas transform into aggressive forms achieve surprisingly better CAR-T cell therapy outcomes than those diagnosed aggressively upfront.
In the largest Italian CAR T-cell registry analysis (n=438), transformed indolent NHL patients receiving anti-CD19 CAR-T achieved substantially better response and survival than de novo DLBCL patients, challenging the conventional assumption that TiNHL has inferior prognosis. This supports CAR-T as a preferred treatment in TiNHL and provides a validated prognostic tool (CAR-HEMATOTOX) for patient selection.
What the study was
- Study design
- Multicenter retrospective/prospective observational study (Italian CAR T-SIE registry)
- Population
- 438 patients with R/R large B-cell lymphoma (107 TiNHL — 96 tFL, 11 tMZL — and 331 dnDLBCL) treated with commercial anti-CD19 CAR T-cell therapy in Italy
- Sample size
- 438
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Journal of Cancer
Why it surfaced
Large multicenter observational study (n=438) demonstrating counter-intuitive finding that TiNHL benefits more from CAR-T than dnDLBCL — this directly impacts treatment strategy and patient selection. The CAR-HEMATOTOX prognostic tool validation adds implementation value.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.